Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 176

1.

Preoperative decision making for renal cell carcinoma: cystic morphology in cross-sectional imaging might predict lower malignant potential.

Huber J, Winkler A, Jakobi H, Bruckner T, Roth W, Hallscheidt P, Daneshvar K, Hohenfellner M, Pahernik S.

Urol Oncol. 2014 Jan;32(1):37.e1-6. doi: 10.1016/j.urolonc.2013.02.016. Epub 2013 Apr 12.

PMID:
23587431
2.

Three-dimensional tumour volume and cancer-specific survival for patients undergoing nephrectomy to treat pT1 clear-cell renal cell carcinoma.

Jorns J, Thiel DD, Lohse CM, Williams A, Arnold ML, Cheville JC, Leibovich BC, Parker AS.

BJU Int. 2012 Oct;110(7):956-60. doi: 10.1111/j.1464-410X.2012.10937.x. Epub 2012 Feb 2.

3.

Prognostic factors influencing long-term survival of patients undergoing nephron-sparing surgery for nonmetastatic renal-cell carcinoma (RCC) with imperative indications.

Haferkamp A, Kurosch M, Pritsch M, Hatiboglu G, Macher-Goeppinger S, Pfitzenmaier J, Pahernik S, Wagener N, Hohenfellner M.

Ann Surg Oncol. 2010 Feb;17(2):544-51. doi: 10.1245/s10434-009-0812-y. Epub 2009 Dec 1.

PMID:
19953334
4.

Multilocular cystic renal cell carcinoma: a series of 12 cases and review of the literature.

Nassir A, Jollimore J, Gupta R, Bell D, Norman R.

Urology. 2002 Sep;60(3):421-7. Review.

PMID:
12350478
5.

Metastatic potential of a renal mass according to original tumour size at presentation.

Umbreit EC, Shimko MS, Childs MA, Lohse CM, Cheville JC, Leibovich BC, Blute ML, Thompson RH.

BJU Int. 2012 Jan;109(2):190-4; discussion 194. doi: 10.1111/j.1464-410X.2011.10184.x. Epub 2011 May 9.

6.

Prognostic implications of the immunohistochemical expression of human kallikreins 5, 6, 10 and 11 in renal cell carcinoma.

Petraki CD, Gregorakis AK, Vaslamatzis MM, Papanastasiou PA, Yousef GM, Levesque MA, Diamandis EP.

Tumour Biol. 2006;27(1):1-7. Epub 2005 Dec 8.

PMID:
16340244
7.

Simple enucleation for the treatment of renal cell carcinoma between 4 and 7 cm in greatest dimension: progression and long-term survival.

Carini M, Minervini A, Lapini A, Masieri L, Serni S.

J Urol. 2006 Jun;175(6):2022-6; discussion 2026.

PMID:
16697790
8.

Late recurrence of renal cell carcinoma >5 years after surgery: clinicopathological characteristics and prognosis.

Park YH, Baik KD, Lee YJ, Ku JH, Kim HH, Kwak C.

BJU Int. 2012 Dec;110(11 Pt B):E553-8. doi: 10.1111/j.1464-410X.2012.11246.x. Epub 2012 May 11.

9.

The impact of temporal presentation on clinical and pathological outcomes for patients with sporadic bilateral renal masses.

Boorjian SA, Crispen PL, Lohse CM, Leibovich BC, Blute ML.

Eur Urol. 2008 Oct;54(4):855-63. doi: 10.1016/j.eururo.2008.04.079. Epub 2008 May 9.

PMID:
18487007
10.

Chromophobe renal cell carcinoma (RCC): oncological outcomes and prognostic factors in a large multicentre series.

Volpe A, Novara G, Antonelli A, Bertini R, Billia M, Carmignani G, Cunico SC, Longo N, Martignoni G, Minervini A, Mirone V, Simonato A, Terrone C, Zattoni F, Ficarra V; Surveillance and Treatment Update on Renal Neoplasms (SATURN) Project; Leading Urological No-Profit Foundation for Advanced Research (LUNA) Foundation.

BJU Int. 2012 Jul;110(1):76-83. doi: 10.1111/j.1464-410X.2011.10690.x. Epub 2011 Nov 1.

11.

Nephron-sparing surgery for renal cell carcinoma: clinicopathologic features predictive of patient outcome.

Krejci KG, Blute ML, Cheville JC, Sebo TJ, Lohse CM, Zincke H.

Urology. 2003 Oct;62(4):641-6. Review.

PMID:
14550434
12.

Prognosis and characteristics of renal cell carcinoma in hemodialysis patients: bilateral occurrence does not influence cancer-specific survival.

Takagi T, Kondo T, Izuka J, Kobayashi H, Tomita E, Hashimoto Y, Tanabe K.

Int J Urol. 2011 Dec;18(12):806-12. doi: 10.1111/j.1442-2042.2011.02852.x. Epub 2011 Sep 14.

13.

Nephron sparing surgery for appropriately selected renal cell carcinoma between 4 and 7 cm results in outcome similar to radical nephrectomy.

Leibovich BC, Blute M, Cheville JC, Lohse CM, Weaver AL, Zincke H.

J Urol. 2004 Mar;171(3):1066-70.

PMID:
14767272
14.
15.

Clinicopathological features and prognosis of synchronous bilateral renal cell carcinoma: an international multicentre experience.

Klatte T, Wunderlich H, Patard JJ, Kleid MD, Lam JS, Junker K, Schubert J, Böhm M, Allhoff EP, Kabbinavar FF, Crepel M, Cindolo L, De La Taille A, Tostain J, Mejean A, Soulie M, Bellec L, Bernhard JC, Ferriere JM, Pfister C, Albouy B, Colombel M, Zisman A, Belldegrun AS, Pantuck AJ.

BJU Int. 2007 Jul;100(1):21-5. Epub 2007 Apr 13.

16.

Comparison of presentation and outcome for patients 18 to 40 and 60 to 70 years old with solid renal masses.

Gillett MD, Cheville JC, Karnes RJ, Lohse CM, Kwon ED, Leibovich BC, Zincke H, Blute ML.

J Urol. 2005 Jun;173(6):1893-6.

PMID:
15879770
17.

Features and outcomes of renal cell carcinoma of native kidneys in renal transplant recipients.

Klatte T, Seitz C, Waldert M, de Martino M, Kikic Z, Böhmig GA, Haitel A, Schmidbauer J, Marberger M, Remzi M.

BJU Int. 2010 May;105(9):1260-5. doi: 10.1111/j.1464-410X.2009.08941.x. Epub 2009 Oct 10.

18.

The influence of pNx/pN0 grouping in a multivariate setting for outcome modeling in patients with clear cell renal cell carcinoma.

Ward JF, Blute ML, Cheville JC, Lohse CM, Weaver AL, Zincke H.

J Urol. 2002 Jul;168(1):56-60.

PMID:
12050492
19.

Cyst-associated renal cell carcinoma: clinicopathologic characteristics and evaluation of prognosis in 27 cases.

Onishi T, Oishi Y, Goto H, Tomita M, Abe K, Sugaya S.

Int J Urol. 2001 Jun;8(6):268-74.

20.

[Chromophobe renal cell carcinoma: a clinicopathological study of 16 cases].

Nakaigawa N, Yao M, Kondo K, Kishida T, Noguchi K, Kubota Y, Nagashima Y, Kawano N, Inayama Y, Nozawa A.

Hinyokika Kiyo. 2006 Jan;52(1):1-6. Japanese.

PMID:
16479980
Items per page

Supplemental Content

Write to the Help Desk